Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 06, 2023 | June 08, 2023 |
| Boundless Bio, Inc.BOLD · Entity 7063 | 10% owner | July 01, 2026 | July 06, 2026 |
| DA32 Life Science Tech Acquisition Corp.DALS · Entity 110669 | 10% owner | July 28, 2023 | August 10, 2023 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | June 08, 2023 | June 09, 2023 |
| Kardigan, Inc.KARD · Entity 4569 | Director · 10% owner | June 22, 2026 | June 24, 2026 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | 10% owner | March 06, 2026 | March 09, 2026 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | 10% owner | January 30, 2025 | January 30, 2025 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 24, 2021 | May 25, 2021 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director · 10% owner | May 27, 2026 | May 29, 2026 |
| Prime Medicine, Inc.PRME · Entity 5281 | 10% owner | August 01, 2025 | August 01, 2025 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | 10% owner | June 10, 2024 | June 10, 2024 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | 10% owner | February 08, 2024 | February 12, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director | July 01, 2026 | July 06, 2026 |
| Seaport Therapeutics, Inc.SPTX · Entity 4799 | 10% owner | May 04, 2026 | May 04, 2026 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director · 10% owner | May 30, 2019 | June 03, 2019 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Director | June 24, 2021 | June 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.33 · Expires 2033-06-06 | Direct | 16,532 |
Reported balance
After 2023-06-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-06 · Grant · Acquired 16,532 · Balance 16,532 F4: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,721,520 |
Reported balance
Holding disclosure · report date 2023-06-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,721,520 F1: Reflects change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person as a result of a distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The reporting person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,721,519 |
Reported balance
Holding disclosure · report date 2023-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,721,519 F1: Reflects change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person as a result of a distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The reporting person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 26,011 |
Reported balance
Holding disclosure · report date 2023-06-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 26,011 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person as a result of a distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The reporting person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
F3: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The reporting person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
F4: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Boundless Bio, Inc.
Report date July 01, 2026 · Filed July 06, 2026
Jointly reported with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Last balance in matching sequence
After 2026-07-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-01 · Exercise / conversion · Acquired 16,000 · Balance 16,000 F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. Row 2 · 2026-07-01 · Sale · Disposed 16,000 · Balance 0 F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-06-22 | IndirectSee footnote | 0 |
Reported balance
After 2026-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-01 · Exercise / conversion · Disposed 16,000 · Balance 0 F7: The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders. F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 683,759 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 683,759 F2: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 828,570 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 828,570 F3: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,181,766 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,181,766 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Kristina Burow, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer.
F2: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F3: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Kristina Burow, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F7: The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders.
DA32 Life Science Tech Acquisition Corp.
Report date July 28, 2023 · Filed August 10, 2023
Jointly reported with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-28 · Other · Disposed 1,600,000 · Balance 0 F1: On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share. F2: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class B Common Stock and shares of Class A common stock purchased in a private placement and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectThrough DA32 Sponsor LLC | 650,000 |
Reported balance
Holding disclosure · report date 2023-07-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 650,000 F2: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class B Common Stock and shares of Class A common stock purchased in a private placement and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. F3: DA32 Sponsor LLC ("Sponsor") owns 650,000 shares of Class A common stock purchased in a private placement concurrently with the Issuer's initial public offering. F4: As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share.
F2: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class B Common Stock and shares of Class A common stock purchased in a private placement and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.
F3: DA32 Sponsor LLC ("Sponsor") owns 650,000 shares of Class A common stock purchased in a private placement concurrently with the Issuer's initial public offering.
F4: As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.
Gossamer Bio, Inc.
Report date June 08, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2033-06-07 | Direct | 35,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 35,000 · Balance 35,000 F1: Award made pursuant to Non-Employee Director Compensation Program. F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award made pursuant to Non-Employee Director Compensation Program.
F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Kardigan, Inc.
Report date June 22, 2026 · Filed June 24, 2026
Jointly reported with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy: ARCH Venture Fund XIII, L.P. | 15,042,035 |
Reported balance
After 2026-06-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-06-22 · Purchase · Acquired 1,250,000 · Balance 15,042,035 F1: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Lyell Immunopharma, Inc.
Report date March 06, 2026 · Filed March 09, 2026
Jointly reported with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,426,528 |
Reported balance
After 2026-03-06 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-03-06 · Purchase · Acquired 488,090 · Balance 1,426,528 F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 910,317 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 910,317 F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 910,317 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 910,317 F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
Maze Therapeutics, Inc.
Report date January 30, 2025 · Filed January 30, 2025
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date. F2: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X Overage, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F5: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F2: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X Overage, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F5: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. |
| Series D-1 Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F6: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D-1 Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F2: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. |
| Series D-1 Preferred StockSEC Table II · derivative / convertible security | IndirectARCH Venture Fund X Overage, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-30 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F6: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D-1 Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date.
F2: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
F4: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
F5: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.
F6: Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D-1 Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.
Metacrine, Inc.
Report date May 24, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.07 · Expires 2031-05-23 | Direct | 16,500 |
Reported balance
After 2021-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-24 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Prime Medicine, Inc.
Report date August 01, 2025 · Filed August 01, 2025
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 6,230,300 |
Reported balance
After 2025-08-01 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-08-01 · Purchase · Acquired 3,030,300 · Balance 6,230,300 F4: Represents shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the general partner of AVP XII LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X, L.P. | 6,128,297 |
Reported balance
Holding disclosure · report date 2025-08-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,128,297 F1: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X Overage, L.P. | 6,128,297 |
Reported balance
Holding disclosure · report date 2025-08-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,128,297 F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
F3: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
F4: Represents shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the general partner of AVP XII LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Rapport Therapeutics, Inc.
Report date June 10, 2024 · Filed June 10, 2024
Jointly reported with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 3,728,738 |
Reported balance
After 2024-06-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-06-10 · Conversion · Acquired 3,728,738 · Balance 3,728,738 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund XII, L.P. | 0 |
Reported balance
After 2024-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-10 · Conversion · Disposed 20,000,000 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund XII, L.P. | 0 |
Reported balance
After 2024-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-10 · Conversion · Disposed 11,924,138 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date.
F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Sana Biotechnology, Inc.
Report date February 08, 2024 · Filed February 12, 2024
Jointly reported with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,667,387 |
Reported balance
After 2024-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-02-08 · Purchase · Acquired 363,637 · Balance 10,667,387 F1: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,446,022 |
Reported balance
After 2024-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2024-02-08 · Purchase · Acquired 727,272 · Balance 12,446,022 F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,446,022 |
Reported balance
After 2024-02-08 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2024-02-08 · Purchase · Acquired 727,272 · Balance 12,446,022 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,301,250 |
Reported balance
Holding disclosure · report date 2024-02-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,301,250 F2: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F2: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F3: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
Scholar Rock Holding Corp
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,605 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 2,105 · Balance 115,605 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3: Consists of 108,766 shares of common stock and 6,839 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 114,657 |
Reported balance
After 2026-07-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-01 · Sale · Disposed 948 · Balance 114,657 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5: Consists of 107,818 shares of common stock and 6,839 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,345,711 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,345,711 F6: The shares are held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. ("GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The GPLP and GPLLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. F7: The managing directors of the GPLLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of the GPLP. The Reporting Person owns an interest in the GPLP but does not have voting or investment control over the shares held by ARCH VIII. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs).
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Consists of 108,766 shares of common stock and 6,839 RSUs.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: Consists of 107,818 shares of common stock and 6,839 RSUs.
F6: The shares are held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. ("GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The GPLP and GPLLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F7: The managing directors of the GPLLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of the GPLP. The Reporting Person owns an interest in the GPLP but does not have voting or investment control over the shares held by ARCH VIII. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
Seaport Therapeutics, Inc.
Report date May 04, 2026 · Filed May 04, 2026
Jointly reported with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 6,294,951 |
Last balance in matching sequence
After 2026-05-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-05-04 · Conversion · Acquired 2,513,686 · Balance 2,513,686 F1: Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Row 2 · 2026-05-04 · Conversion · Acquired 2,681,265 · Balance 5,194,951 F1: Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Row 3 · 2026-05-04 · Purchase · Acquired 1,100,000 · Balance 6,294,951 F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund XII, L.P. | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 2,513,686 · Balance 0 F1: Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy ARCH Venture Fund XII, L.P. | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 2,681,265 · Balance 0 F1: Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Unity Biotechnology, Inc.
Report date June 24, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2031-06-23 | Direct | 25,000 |
Reported balance
After 2021-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-24 · Grant · Acquired 25,000 · Balance 25,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Erasca, Inc.
Report date July 20, 2021 · Filed July 21, 2021
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, GILLIS STEVEN
Section 16 reporting ended · disclosed 2021-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X, L.P. | 5,527,777 |
Reported balance
After 2021-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-20 · Conversion · Acquired 5,527,777 · Balance 5,527,777 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X Overage, L.P. | 5,527,777 |
Reported balance
After 2021-07-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-07-20 · Conversion · Acquired 5,527,777 · Balance 5,527,777 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-20 · Conversion · Disposed 2,100,000 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X Overage, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-20 · Conversion · Disposed 2,100,000 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-20 · Conversion · Disposed 3,400,000 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-20 · Conversion · Disposed 1,133,333 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X Overage, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-20 · Conversion · Disposed 3,400,000 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy ARCH Venture Fund X Overage, L.P. | 0 |
Reported balance
After 2021-07-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-07-20 · Conversion · Disposed 1,133,333 · Balance 0 F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.
F2: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.
F3: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.
Metsera, Inc.
Report date November 13, 2025 · Filed November 13, 2025
Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 2,688 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-11-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-11-13 · Disposition to issuer · Disposed 17,070,904 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F8: Represents shares of Common Stock held directly by ARCH Venture Fund XII, L.P ("ARCH Venture Fund XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC ("AVP XII LLC"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-11-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-11-13 · Disposition to issuer · Disposed 18,503,128 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F8: Represents shares of Common Stock held directly by ARCH Venture Fund XII, L.P ("ARCH Venture Fund XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC ("AVP XII LLC"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-11-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-11-13 · Disposition to issuer · Disposed 7,523,682 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F9: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-11-13 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2025-11-13 · Disposition to issuer · Disposed 8,313,680 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F9: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,688 |
Reported balance
After 2025-11-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-13 · Grant · Acquired 2,688 · Balance 2,688 F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2035-05-19 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-13 · Disposition to issuer · Disposed 16,125 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2034-11-11 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-11-13 · Disposition to issuer · Disposed 148,953 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F7: This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus
F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,
F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.
F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.
F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.
F7: This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024.
F8: Represents shares of Common Stock held directly by ARCH Venture Fund XII, L.P ("ARCH Venture Fund XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC ("AVP XII LLC"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.
F9: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.
Verve Therapeutics, Inc.
Report date June 21, 2021 · Filed June 23, 2021
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectARCH Venture Fund X, L.P. | 1,254,404 |
Reported balance
After 2021-06-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-21 · Conversion · Acquired 1,254,404 · Balance 1,254,404 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F1: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectARCH Venture Fund X Overage, L.P. | 1,254,405 |
Reported balance
After 2021-06-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-06-21 · Conversion · Acquired 1,254,405 · Balance 1,254,405 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-06-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-21 · Conversion · Disposed 7,107,024 · Balance 0 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F5: The expiration date is not relevant to the conversion of these securities. F1: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-06-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-21 · Conversion · Disposed 7,107,023 · Balance 0 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F5: The expiration date is not relevant to the conversion of these securities. F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-06-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-21 · Conversion · Disposed 4,508,144 · Balance 0 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F5: The expiration date is not relevant to the conversion of these securities. F1: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-06-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-21 · Conversion · Disposed 4,508,146 · Balance 0 F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. F5: The expiration date is not relevant to the conversion of these securities. F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F2: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F3: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
F4: The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering.
F5: The expiration date is not relevant to the conversion of these securities.
Vir Biotechnology, Inc.
Report date May 21, 2020 · Filed October 13, 2020 · Amendment
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.06 · Expires 2030-05-20 | Direct | 25,404 |
Reported balance
After 2020-05-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-05-21 · Grant · Acquired 25,404 · Balance 25,404 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2023 Filed Sep 29, 2023 22:55 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 34,560 | $13.98 | $483,148.80 |
DisclosureSEC source: 0001062993-23-018633 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,859,898 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.48 to $14.11, inclusive. F4 · ownership.nature: Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 22:55 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 25,110 | $13.69 | $343,755.90 |
DisclosureSEC source: 0001062993-23-018633 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,825,338 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.34 to $14.23, inclusive. F4 · ownership.nature: Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 22:55 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 16,841 | $13.06 | $219,943.46 |
DisclosureSEC source: 0001062993-23-018633 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,800,228 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.33, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F4 · ownership.nature: Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 27, 2023 Filed Sep 28, 2023 00:19 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 24,504 | $12.31 | $301,644.24 |
DisclosureSEC source: 0001062993-23-018548 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,783,387 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.94 to $12.68, inclusive. F3 · ownership.nature: Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 00:19 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 34,000 | $11.73 | $398,820.00 |
DisclosureSEC source: 0001062993-23-018548 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,758,883 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.32 to $12.04, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F3 · ownership.nature: Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:37 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 29,967 | $11.65 | $349,115.55 |
DisclosureSEC source: 0001062993-23-018468 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,724,883 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.50 to $12.14, inclusive. F4 · ownership.nature: Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:37 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 30,773 | $10.80 | $332,348.40 |
DisclosureSEC source: 0001062993-23-018468 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,694,916 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.49, inclusive. F4 · ownership.nature: Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 01:37 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 40,000 | $11.14 | $445,600.00 |
DisclosureSEC source: 0001062993-23-018468 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,664,143 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.48, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1),(2), and (3) to this Form 4. F4 · ownership.nature: Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries B Preferred Stock · Derivative | 2,124,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 13 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,124,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F8 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-2 Preferred Stock · Derivative | 6,576,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 12 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 6,576,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F7 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-2 Preferred Stock · Derivative | 6,895,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 11 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 6,895,021 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F7 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-1 Preferred Stock · Derivative | 1,144,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 10 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,144,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. AVP VIII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VIII LLC and owns an interest in AVP VIII LLC but does not have voting or investment control over the shares held by ARCH VIII Overage. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-1 Preferred Stock · Derivative | 684,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 9 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 684,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. AVP VII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VII LLC and owns an interest in AVP VII LP but does not have voting or investment control over the shares held by ARCH VII. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-1 Preferred Stock · Derivative | 13,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · derivative · entry 8 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 1,500,000 | $17.00 | $25,500,000.00 |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 7 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,624,143 F8 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 2,124,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 6 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,124,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F8 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 6,576,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 5 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 11,886,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F7 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 6,895,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 4 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 12,205,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F7 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 1,144,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,144,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. AVP VIII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VIII LLC and owns an interest in AVP VIII LLC but does not have voting or investment control over the shares held by ARCH VIII Overage. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 684,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 684,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. AVP VII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VII LLC and owns an interest in AVP VII LP but does not have voting or investment control over the shares held by ARCH VII. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:23 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 13,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000291 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:54 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000284 · form4.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-13 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| July 28, 2023 Filed Aug 10, 2023 20:27 UTC | DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669 | OtherClass A Common Stock | 1,600,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-016233 · form4.xml · nonDerivative · entry 1 ARCH Venture Fund XI, L.P. · CIK 0001831802 · 10% owner ARCH Venture Partners XI, L.P. · CIK 0001847567 · 10% owner ARCH Venture Partners XI, LLC · CIK 0001847601 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share. F1 · price: On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share. F2 · ownership.direct: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class B Common Stock and shares of Class A common stock purchased in a private placement and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 11:34 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001415889-23-010215 · form4-06232023_110628.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001728117-23-000078 · wf-form4_168634158506142.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-07 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:02 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 16,532 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0000950170-23-027060 · ownership.xml · derivative · entry 4 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,532 Underlying: Common Stock · 16,532 shares Expires 2033-06-06 F4 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,141,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · derivative · entry 8 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 367,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Reflects shares purchased by ARCH X in the Issuer's initial public offering. F5 · derivative.exercise_date: Reflects shares purchased by ARCH X in the Issuer's initial public offering. F5 · derivative.expiration_date: Reflects shares purchased by ARCH X in the Issuer's initial public offering. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,141,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · derivative · entry 7 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 367,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionSeries A Convertible Preferred Stock · Derivative | 16,666,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · derivative · entry 6 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 5,361,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionSeries A Convertible Preferred Stock · Derivative | 16,666,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · derivative · entry 5 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P Disclosed balance after: 0 Underlying: Common Stock · 5,361,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 400,000 | $17.00 | $6,800,000.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · nonDerivative · entry 4 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 6,128,297 F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F6 · ownership.nature: Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 400,000 | $17.00 | $6,800,000.00 |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · nonDerivative · entry 3 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 6,128,297 F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F5 · ownership.nature: Reflects shares purchased by ARCH X in the Issuer's initial public offering. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionCommon Stock | 5,728,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · nonDerivative · entry 2 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 5,728,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionCommon Stock | 5,728,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-027125 · wf-form4_166682887797580.xml · nonDerivative · entry 1 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 5,728,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X. F3 · ownership.nature: ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 10,391 | $0.00 Strike: $55.58 | $0.00 |
DisclosureSEC source: 0000899243-22-030277 · doc4.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Underlying: Common Stock · 10,391 shares Expires 2032-09-01 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 09, 2022 Filed Jul 15, 2022 21:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001728117-22-000078 · wf-form4_165792005588771.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-08 F1 · kind: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:32 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001104659-22-065950 · tm2216969-3_4seq1.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:31 UTC | DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669 | OtherClass B Common Stock, par value $0.0001 per share · Derivative | 701,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032264 · doc4.xml · derivative · entry 1 ARCH Venture Fund XI, L.P. · CIK 0001831802 · 10% owner · Member of 10% owner group ARCH Venture Partners XI, L.P. · CIK 0001847567 · 10% owner ARCH Venture Partners XI, LLC · CIK 0001847601 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Through DA32 Sponsor LLC Disclosed balance after: 4,465,000 Underlying: Class A Common Stock · 701,250 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. F2 · kind: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. F1 · derivative.exercise_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. F1 · derivative.expiration_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. F2 · derivative.underlying_shares: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. F3 · ownership.nature: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class A Common Stock and Class B Common Stock and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. F4 · ownership.nature: As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:06 UTC | DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669 | OtherClass A Common Stock | 650,000 | $10.00 | $6,500,000.00 |
DisclosureSEC source: 0000899243-21-031417 · doc4.xml · nonDerivative · entry 2 ARCH Venture Fund XI, L.P. · CIK 0001831802 · 10% owner ARCH Venture Partners XI, L.P. · CIK 0001847567 · 10% owner ARCH Venture Partners XI, LLC · CIK 0001847601 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Through A32 ponsor LC Disclosed balance after: 2,250,000 F4 · security: As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. F3 · kind: DA32 Sponsor LLC ("Sponsor") purchased 650,000 shares of Class A common stock directly from the Issuer in a private placement for $10.00 per share, concurrently with the Issuer's initial public offering. F3 · shares: DA32 Sponsor LLC ("Sponsor") purchased 650,000 shares of Class A common stock directly from the Issuer in a private placement for $10.00 per share, concurrently with the Issuer's initial public offering. F2 · ownership.nature: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class A common stock and Class B Common Stock and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. F4 · ownership.nature: As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:06 UTC | DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669 | PurchaseClass A Common Stock | 1,600,000 | $10.00 | $16,000,000.00 |
DisclosureSEC source: 0000899243-21-031417 · doc4.xml · nonDerivative · entry 1 ARCH Venture Fund XI, L.P. · CIK 0001831802 · 10% owner ARCH Venture Partners XI, L.P. · CIK 0001847567 · 10% owner ARCH Venture Partners XI, LLC · CIK 0001847601 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600,000 F1 · kind: ARCH Venture Fund XI, L.P. purchased 1,600,000 shares of the Issuer's Class A common stock for $10.00 per share in the Issuer's initial public offering. F2 · ownership.direct: This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class A common stock and Class B Common Stock and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-2 Preferred Stock · Derivative | 1,133,333 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 8 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 944,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-1 Preferred Stock · Derivative | 3,400,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 7 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,833,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-2 Preferred Stock · Derivative | 1,133,333 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 6 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 944,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-1 Preferred Stock · Derivative | 3,400,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 5 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,833,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries A Preferred Stock · Derivative | 2,100,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 4 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,750,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries A Preferred Stock · Derivative | 2,100,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 3 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,750,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionCommon Stock | 5,527,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · nonDerivative · entry 2 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 5,527,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:53 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionCommon Stock | 5,527,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029077 · doc4.xml · nonDerivative · entry 1 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Burow Kristina · CIK 0001569248 · 10% owner GILLIS STEVEN · CIK 0001229592 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 5,527,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:20 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 2,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006294 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,067 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:20 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006294 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The Reporting Person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.